Both Therapix Biosciences Ltd. (NASDAQ:TRPX) and Kodiak Sciences Inc. (NASDAQ:KOD) are Biotechnology companies, competing one another. We will contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Therapix Biosciences Ltd.	N/A	0.00	7.71M	-2.12	0.00
Kodiak Sciences Inc.	N/A	0.00	41.44M	-1.07	0.00

Demonstrates Therapix Biosciences Ltd. and Kodiak Sciences Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows us Therapix Biosciences Ltd. and Kodiak Sciences Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Therapix Biosciences Ltd.	0.00%	0%	0%
Kodiak Sciences Inc.	0.00%	0%	0%

Analyst Recommendations

Therapix Biosciences Ltd. and Kodiak Sciences Inc. Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Therapix Biosciences Ltd.	0	0	0	0.00
Kodiak Sciences Inc.	0	0	1	3.00

Competitively Kodiak Sciences Inc. has an average price target of $22.5, with potential upside of 206.12%.

Institutional & Insider Ownership

The shares of both Therapix Biosciences Ltd. and Kodiak Sciences Inc. are owned by institutional investors at 0% and 48.2% respectively. Therapix Biosciences Ltd.’s share held by insiders are 2.08%. On the other hand, insiders held about 11.8% of Kodiak Sciences Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Therapix Biosciences Ltd.	10.12%	25.81%	-18.04%	5.64%	-14.6%	44%
Kodiak Sciences Inc.	1.45%	-8.98%	-24.19%	0%	0%	-1.55%

For the past year Therapix Biosciences Ltd. has 44% stronger performance while Kodiak Sciences Inc. has -1.55% weaker performance.

Summary

On 3 of the 5 factors Kodiak Sciences Inc. beats Therapix Biosciences Ltd.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Tel Aviv, Israel.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.